Substitute form 1449	A/PTO /	7910	Compl te if Known		
		6/	Application Number	09/525,797	
INFORMATION I	DISCLOSURE.		Filing Date	03/15/2000	
STATEMENT BY	' APPLICANT#	4/2.4	First Named Inventor	Athanasius A. Anagnostou	
	E	· ' 2003 · S	Group Art Unit	1642	
(use as many sheets	as necessary)		Examiner Name	Susan Ungar	
Sheet 1	of	Ran WEY	Attorney Docket Number	5218-39B	

			U.S. PATE	NTS AND PATENT PUBLICATION	NS	
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages
	··············		Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY
	ļ					
	<u> </u>	•				70
	 					-S.O~
	 			, , , , , , , , , , , , , , , , , , , ,		
	 			<u> </u>		(En, 06)
	 	· · · · · · · · · · · · · · · · · · ·	<u> </u>			14/CA 25
	 			· · · · · · · · · · · · · · · · · · ·		1 1/1/2× 100
	1		- 			1/80
	 					1000/20
	 	· · · · · · · · · · · · · · · · · · ·				150
	i -	·		 		
				· · · · · · · · · · · · · · · · · · ·		

	_			FOREIGN	PATENT DOCUMENTS			
	Cite No.	Foreign Patent Document			Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	T
	NO.	Office	Number	Kind Code (if known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
CN	1	JP	02 096535	Α	Chugai Pharm Co Ltd	04/09/1990	Abstract	
·····								
					,			
		 				 		
•		T				<u> </u>		

		OTHER NON PATENT LITERATURE DOCUMENTS	\neg
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	dú
****	-2 ·	Communication with Supplementary European Search Report, EP 97 94 0974, July 15, 2002	Fle
SM	3	Bukowski et al., Phase IV evaluation of clinical outcomes of PROCRIT (Epoetin alfa) in anemic cancer patients receiving chemotherapy, Blood, Journal of the American Society of Hematology, Vol. 84, No. 10, Supp. 1, December 1994, p. 129A	
	4	Taylor et al., Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin, Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis, Vol. 6, No. 2, April 1995, pp. 100-104	
	5	Taylor et al., Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients, Kidney International, Vol. 44, No. 1, July 1993, pp. 182-190	
P	6	Reinhart, Shear-dependence of endothelial functions, Experientia, Vol. 50, No. 2, February 15, 1994, pp. 87-93	
	7	U.S. Patent Application Serial No. 09/525,808, filed March 15, 2000	90
			\exists
			\dashv

		/ /		•	
Examiner Signature	1	\overline{V}	4-	Date Considered	
			10-	5/7/07	

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.